Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 17/20 | 0.70 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.70 |
| ▸ | ERBB4 | Q15303 | 4/20 | 0.67 |
| ▸ | BTK | Q06187 | 1/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.51 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.51 |
| ▸ | ROS1 | P08922 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 1/20 | 0.51 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.51 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.51 |
| ▸ | AURKA | O14965 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7245617 | 0.91 | EGFR (0.73) | EGFRERBB2ERBB4BTKAURKB | |
| SCHEMBL7244172 | 0.90 | EGFR (0.61) | EGFRERBB2ERBB4BTKAURKB | |
| SCHEMBL7236868 | 0.90 | ERBB2 (0.69) | EGFRERBB2ERBB4AURKBAURKA | |
| SCHEMBL7241925 | 0.89 | EGFR (0.56) | EGFRERBB2ERBB4AURKBCHEK2 | |
| SCHEMBL7239406 | 0.83 | EGFR (0.72) | EGFRERBB2ERBB4AURKBCHEK2 | |
| SCHEMBL7127194 | 0.83 | EGFR (0.68) | EGFRERBB2ERBB4BTK | |
| SCHEMBL30115350 | 0.82 | EGFR (1.00) | EGFRERBB2ERBB4 | |
| SCHEMBL7237483 | 0.81 | EGFR (0.63) | EGFRERBB2ERBB4BTKAURKB | |
| SCHEMBL7241852 | 0.81 | EGFR (0.62) | EGFRERBB2AURKBAURKA | |
| SCHEMBL7239509 | 0.81 | EGFR (0.72) | EGFRERBB2ERBB4BTKAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | claimed |
| US-6127374-A | AN ENZYME INHIBITOR FOR TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS AND PSORIASIS | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | claimed |
| US-6562818-B1 | For treating cancer, atherosclerosis, restenosis, endometriosis, and psoriasis | WARNER-LAMBERT COMPANY | 2003-05-13 | — | — | US | disclosed |
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | BRIDGES ALEXANDER JAMES (US) | 2003-05-08 | — | — | US | disclosed |
| US-6127374-A | AN ENZYME INHIBITOR FOR TREATING CANCER, RESTENOSIS, ATHEROSCLEROSIS, ENDOMETRIOSIS AND PSORIASIS | WARNER-LAMBERT COMPANY (US) | 2000-10-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087881-A1 | Irreversible inhibitors of tyrosine kinases | ERBB2, ERBB3, LCK | EGFR 26/4885ERBB2 1/4885ERBB4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.